首页>
外国专利>
Use of composition of zalpha11 ligand antagonist, compositions comprising zalpha11 ligand antagonist, a method of producing an antagonist and an antagonist produced by the method
Use of composition of zalpha11 ligand antagonist, compositions comprising zalpha11 ligand antagonist, a method of producing an antagonist and an antagonist produced by the method
The invention provides a fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide that comprises a sequence of amino acid residues from 41 to 56 of SEQ ID NO:2; a first spacer of 6-27 amino acid residues; a second polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix B residues 53-75 of SEQ ID NO:111; (b) IL-4 helix B residues 65-83 of SEQ ID NO:112; (c) IL-15 helix B residues 84-101 of SEQ ID NO:113; (d) GMCSF helix B residues 72-81 of SEQ ID NO:114; and (e) amino acid residues 69-84 of SEQ ID NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 87-99 of SEQ ID NO:111; (b) IL-4 helix C residues 95-118 of SEQ ID NO:112; (c) IL-15 helix C residues 107-119 of SEQ ID NO:113; (d) GMCSF helix C residues 91-102 of SEQ ID NO:2; (e) amino acid residues 92-105 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix D residues 103-121 of SEQ ID NO:111; (b) IL-15 helix D residues 134-157 of SEQ ID NO:112; (c) IL-4 helix D residues 134-160 of SEQ ID NO:113; (d) GMCSF helix D residues 120-131 of SEQ ID NO:114; and (e) amino acid residues 135-148 of SEQ ID NO:2.
展开▼
机译：本发明提供了包含至少四个多肽的融合蛋白，其中多肽从N末端到C末端的顺序是：第一多肽，其包含SEQ ID NO：2的41至56个氨基酸残基的序列;和6-27个氨基酸残基的第一间隔子;第二多肽，其包含选自以下的氨基酸残基的序列：（a）SEQ ID NO：111的IL-2螺旋B残基53-75; （b）SEQ ID NO：112的IL-4螺旋B残基65-83; （c）SEQ ID NO：113的IL-15螺旋B残基84-101; （d）SEQ ID NO：114的GMCSF螺旋B残基72-81; （e）SEQ ID NO：2的氨基酸残基69-84; 5-11个氨基酸残基的第二个间隔基;第三多肽，其包含选自以下的氨基酸残基的序列：（a）SEQ ID NO：111的IL-2螺旋C残基87-99; （b）SEQ ID NO：112的IL-4螺旋C残基95-118; （c）SEQ ID NO：113的IL-15螺旋C残基107-119; （d）SEQ ID NO：2的GMCSF螺旋C残基91-102; （e）SEQ ID NO：2的氨基酸残基92-105; 3-29个氨基酸残基的第三个间隔子;第四多肽，其包含选自以下的氨基酸残基的序列：（a）SEQ ID NO：111的IL-2螺旋D残基103-121; （b）SEQ ID NO：112的IL-15螺旋D残基134-157; （c）SEQ ID NO：113的IL-4螺旋D残基134-160; （d）SEQ ID NO：114的GMCSF螺旋D残基120-131; （e）SEQ ID NO：2的氨基酸残基135-148。
展开▼
